Here are relevant reports on : sexually-transmitted-diseases-testing-market
-
Urology Surgical Instruments Market by Product (Endoscopes, Endovision Systems, Peripheral Instruments, Consumables and Accessories), Application (Chronic Kidney Diseases, Benign Prostatic Hyperplasia, Oncology) - Global Forecast to 2021
The global urology surgical instruments market size is projected to grow at a CAGR of 8.2%. The growth of this market can be contributed to rising prevalence of kidney diseases and urinary tract infections; rising number of hospitals and growing hospital investments in surgical infrastructure; availability of investments, funds, and grants from government bodies; and rising geriatric population.
- Published: September 2016
- Price: $ 4950
- TOC Available:
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024
The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: October 2026
- Price: $ 4950
- TOC Available:
-
PEGylated Proteins Market by Consumables (PEGylation Kits, Reagents), Services, Protein Type (mAbs, Interferons), Application (Cancer Treatment, Chronic Kidney Diseases), End-User (Pharmaceutical & Biotechnology Companies)- Global Forecast to 2021
The global PEGylated proteins market size is projected to grow at a CAGR of 10.5%. The major drivers for the market include increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing focus on strategies to improve protein stability and circulating half-life. The rising opportunities in emerging markets and top-selling biologics drugs going off-patent in the near future will provide new growth opportunities for this market.
- Published: November 2016
- Price: $ 4950
- TOC Available:
-
Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030
The global injectable drug delivery market, valued at USD 633.77 billion in 2024, stood at USD 690.23 billion in 2025 and is projected to advance at a resilient CAGR of 8.4% from 2025 to 2030, culminating in a forecasted valuation of USD 1,034.78 billion by the end of the period. The injectable drug delivery market is driven by the rising prevalence of chronic diseases, such as diabetes, cancer, and autoimmune disorders, alongside an increasing global demand for biologics.
- Published: May 2025
- Price: $ 8150
- TOC Available:
-
Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Western Blot), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Laboratories) - Global Forecast to 2030
The global immunoassay market, valued at US$34.4 billion in 2024, stood at US$35.5 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$47.7 billion by the end of the period. This growth is primarily driven by the increasing prevalence of chronic and infectious diseases worldwide, which has boosted the demand for early and accurate diagnostic solutions.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Exosome Research Market by Offering (Kits, Reagents (Antibodies, Isolation, Purification), Instruments, Services), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem Cell) - Global Forecast to 2030
The global exosome research market, valued at US$189.4 million in 2024, stood at US$214.4 million in 2025 and is projected to advance at a resilient CAGR of 17.5% from 2025 to 2030, culminating in a forecasted valuation of US$480.6 million by the end of the period. The growth of the Asia Pacific exosome research market is primarily due to the growing biomedical industry, increasing life science research, and rising investments by pharmaceutical & biotechnology companies in this region.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
Oxidative Stress Assay Market by Product (Consumable, Instruments, Kits, Services), Test Type (Indirect, nucleic acid, Glutathione, ROS), Technology (ELISA, Chromatography), Diseases (CVD, Oncology) End User (Pharma & Biotech) & Region - Global Forecasts to 2025
The global oxidative stress assay market growth is primed to transition from USD 836 million in 2020 to USD 1,326 million by 2025, showcasing a strong CAGR of 9.7%. Growth in the oxidative stress assay market is attributed to factors such as the biopharmaceutical industry and increasing public-sector funding for academic research.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
Transdermal Drug Delivery System Market by Type (Patches and Semisolid formulations), Applications (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Diseases), End User, and Region - Global Forecast to 2023
The transdermal drug delivery system market is projected to reach USD 7.1 billion by 2023, growing at a CAGR of 4.5%. The growth of this market is primarily driven by factors such as the increase in the prevalence of chronic diseases and technological advancements in transdermal drug delivery systems. The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).
- Published: January 2019
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
